Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. (SPRC) is a clinical-stage pharmaceutical innovator developing cannabinoid-based therapies for neurological disorders while operating a consumer hemp products division. This page provides verified updates on both business segments, serving investors and stakeholders with essential news repository.
Access authoritative information on SPRC's clinical trial advancements, regulatory filings, and financial performance alongside developments in its hemp-derived product line. Content includes press releases detailing research milestones, partnership announcements, and strategic initiatives across therapeutic and consumer markets.
Key updates cover FDA communications, intellectual property developments, quarterly earnings disclosures, and operational expansions. All materials are curated to meet investor needs for decision-making clarity while maintaining compliance with financial reporting standards.
Bookmark this resource for streamlined access to SPRC's official announcements and analysis. Regularly updated content ensures stakeholders stay informed about the company's progress in pharmaceutical innovation and consumer market execution.
SciSparc Ltd. (NASDAQ: SPRC) has signed an escrow agreement following a non-binding letter of intent (LOI) to acquire a top-seller Amazon.com account and related brand from Merhavit M.R.M. Holding and Management Ltd for an initial $1 million deposit. If a definitive agreement is reached, the deposit will contribute to the total purchase. The LOI also includes provisions for management and distribution agreements to enhance product commercialization and expand into new markets. If no agreement is finalized, SciSparc incurs a $50,000 cost but will recover $950,000.
SciSparc Ltd. (NASDAQ: SPRC) has signed a non-binding letter of intent to acquire a top-selling Amazon seller account and a food supplements and cosmetics brand from Merhavit M.R.M Holding. The acquisition includes a management agreement and a distribution agreement, with a base payment of $4.59 million and potential additional payments based on the brand's EBITDA. The deal may enhance SciSparc's market presence and manufacturing capabilities, as the global Industrial Hemp market is projected to grow significantly from $4.1 billion in 2021 to $16.7 billion by 2030.
SciSparc Ltd. (NASDAQ: SPRC) has secured a new patent in Israel for its innovative technology targeting central nervous system disorders. This patent protects pharmaceutical compositions featuring cannabinoids and N-acylethanolamines, aiming to treat various conditions. This milestone marks the fifth patent related to its core technology, reinforcing the company's strong intellectual property portfolio, previously recognized in the U.S., Australia, and Japan. CEO Adi Zuloff-Shani emphasized the importance of this development in distinguishing SciSparc within the pharmaceutical sector.
SciSparc Ltd. (Nasdaq: SPRC) announced the addition of the Yale Child Study Center to its Phase IIb clinical trial for SCI-110, targeting Tourette Syndrome (TS). This site joins Hannover Medical School and Tel Aviv Sourasky Medical Center in the multinational trial. The trial aims to evaluate the efficacy and safety of SCI-110, with positive Phase IIa results showing a 21% reduction in tic symptoms among medication-refractory patients. The trial's data will qualify for submissions to the FDA and EMA, reflecting strong potential for regulatory approval.
SciSparc Ltd. (Nasdaq: SPRC) has initiated preparations for an Investigational New Drug Application (IND) with the FDA for a Phase IIb clinical trial of its drug, SCI-110, targeting Tourette Syndrome (TS). Following promising Phase IIa trial results showing a 21% reduction in tic symptoms among treatment-resistant patients, the company aims to expand clinical sites to the U.S. Approval has been granted by two medical centers in Germany and Israel to participate in the upcoming trial, which will evaluate treatment efficacy and safety.
SciSparc Ltd. (Nasdaq: SPRC) announced the launch of its new advanced facility in Ness-Ziona Science Park, Israel, through its joint venture MitoCareX Bio, aimed at developing anti-cancer drug candidates. This facility underscores the company’s commitment to addressing the global cancer crisis, which accounted for nearly 10 million deaths in 2020. MitoCareX Bio will focus on mitochondrial carriers critical for cell viability and is enhancing its computational drug discovery capabilities, building upon successful proof-of-concept research conducted in the U.K.
SciSparc Ltd. (Nasdaq: SPRC) has announced a $1 million share buyback program, aimed at enhancing shareholder value. The program will require court approval in Israel and is contingent upon the formal approval of financial statements for the six months ending June 30, 2022. The company is engaged in developing cannabinoid-based therapies targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder. This move reflects SciSparc's commitment to delivering shareholder returns amidst ongoing clinical trials.
SciSparc Ltd. (Nasdaq: SPRC) has announced the successful development of its drug candidate SCI-110 for an upcoming Phase IIb trial targeting Tourette Syndrome (TS). The company received ethics committee approvals from institutions in Germany and Israel for the study. SCI-110 aims to provide a safe treatment option for patients with limited alternatives. The multinational study will evaluate the drug's efficacy and safety in adults aged 18-65, focusing on tic severity changes. The trial's launch awaits further regulatory approvals.
SciSparc Ltd. (NASDAQ: SPRC) has received approval from the Soroka University Ethics Committee to conduct a clinical trial for its proprietary drug SCI-210, targeting Autism Spectrum Disorder (ASD). This trial aims to evaluate the safety, tolerability, and efficacy of SCI-210, a combination of cannabidiol and CannAmide™, compared to CBD monotherapy in 60 children over 20 weeks. The approval marks a significant milestone for SciSparc in its pursuit of developing effective treatments for pediatric patients with limited options.
SciSparc Ltd. (Nasdaq: SPRC) announced the appointment of Prof. Ciro Leonardo Pierri as a special advisor for MitoCareX Bio Ltd., its new joint venture focused on drug development for cancers and infectious diseases. Prof. Pierri, a biochemist from the University of Bari, Italy, brings expertise in structural biology and molecular modeling. The JV aims to explore mitochondrial carriers' roles in disease treatment, building on successful proof-of-concept experiments in the UK. SciSparc is engaged in cannabinoid-based drug development, targeting conditions like Tourette syndrome and Alzheimer’s disease.
FAQ
What is the current stock price of Scisparc (SPRC)?
What is the market cap of Scisparc (SPRC)?
